provectus8k62812.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported):   June 28, 2012


PROVECTUS PHARMACEUTICALS, INC.
 (Exact name of registrant as specified in charter)



Nevada
0-9410
90-0031917
(State or other jurisdiction
(Commission
(IRS Employer
of  incorporation)
File Number)
Identification No.)


7327 Oak Ridge Hwy., Knoxville, Tennessee 37931
(Address of Principal Executive Offices)

(866) 594-5999
(Registrant’s Telephone Number, Including Area Code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
□
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
□
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
□
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
□
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 
 
 
 
Item 5.07.  Submission of Matters to a Vote of Security Holders.

(a)
Provectus Pharmaceuticals, Inc. (the "Company") held its annual meeting of stockholders on Thursday, June 28, 2012.
 
 
(b)  At the annual meeting, the Company's stockholders voted on four proposals.  A brief description of and tabulation of votes for each proposal are set forth below.
   
  Proposal 1.  The Company's stockholders elected the following directors for a term of one year.  There were 42,195,732 broker non-votes with respect to the proposal.
 
          
   
Nominee
For
  
Withheld
 
 
 H. Craig Dees, Ph.D.
35,391,511
 1,954,206
 
  Timothy C. Scott, Ph.D.
35,380,961
 1,964,756
 
  Kelly M. McMasters, M.D., Ph.D.
35,441,767
 1,903,950
 
  Alfred E. Smith, IV
35,445,867
 1,899,850
 

 
While Eric A. Wachter was nominated to the Company's Board of Directors (the "Board"), subsequent to the delivery of the Company's proxy statement to the Company's stockholders in connection with the Company's annual meeting, Dr. Wachter resigned from the Board effective May 14, 2012.  Jan E. Koe was appointed to the Board on May 14, 2012 to fill the vacancy created by Dr. Wachter's resignation, as disclosed in the Company's Form 8-K filed with the Commission on May 14, 2012.
 
Proposal 2.  The Company's stockholders approved the Company's 2012 Stock Plan. There were 42,195,732 broker non-votes with respect to the proposal.
 
 
   
For
  
Against
  
Abstain
  
   31,005,697  5,973,390  366,630  
 
 
Proposal 3.  The Company's stockholders approved the advisory vote on the compensation of the Company's named executive officers. There were 42,195,732 broker non-votes with respect to the proposal.
 
 
   
For
  
Against
  
Abstain
  
   26,928,812  7,601,273  2,815,632  
 
 
Proposal 4.  The Company's stockholders ratified the selection of BDO USA, LLP as the Company's independent auditor for 2012. There were no broker non-votes with respect to the proposal.
 
 
   
For
  
Against
  
Abstain
  
   78,060,459  649,660
831,330
  
 

 

 
 
 

 
SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:  July 2, 2012
 
 
PROVECTUS PHARMACEUTICALS, INC.
 
  
       
 
By:
/s/ Peter R. Culpepper  
    Peter R. Culpepper  
    Chief Financial Officer and Chief Operating Officer